{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:31Z","timestamp":1788623851640,"version":"build-2803163510"},"reference-count":41,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:p>Angioedema is nonpitting swelling that involves the deeper subcutaneous and submucosal layers of tissue. Angioedema can be classified as histaminergic, bradykinin mediated, or idiopathic in etiology. Bradykinin-mediated angioedema presents without urticaria, whereas histaminergic angioedema\n is usually associated with urticaria (i.e., chronic spontaneous urticaria and angioedema) but manifests with isolated angioedema in \u223c20% of patients and clinically overlaps with idiopathic angioedema. Bradykinin-mediated angioedema most commonly occurs in hereditary angioedema (HAE) with\n or without C1-esterase inhibitor (C1-INH) (HAE-C1INH) deficiency, acquired C1-INH deficiency, and angiotensin-converting enzyme (ACE) inhibitor angioedema. HAE is a life-threatening genetic autosomal dominant disorder most commonly due to a mutation in the serpin family G member 1 (SERPING1)\n gene, which leads to a deficiency in C1-INH, although multiple new genetic mutations have also been described in HAE with normal C1-INH (HAE\u2010nl-C1INH) level. Clinically, patients have edema that can lead to life-threatening laryngeal edema and asphyxiation. HAE\u2010nl-C1INH describes\n patients with similar symptoms to those with HAE\u2010C1INH deficiency but have normal C1-INH function and are distinguished by various genetic mutations and a family history of angioedema. Acquired C1-INH deficiency also mimics HAE with symptoms but is due to circulating anti-idiotypic\n antibodies, leading to either C1-INH consumption or inactivation. Patients are often diagnosed with underlying malignant, lymphoproliferative, or autoimmune disorders. ACE-inhibitor angioedema classically presents with facial, tongue, and oral cavity swelling not associated with pruritus accompanied\n by normal laboratory studies. Treatment involves stopping the ACE inhibitor though recurrence can occur for a few weeks to months after discontinuation. Idiopathic angioedema is the largest category and is diagnosed when patients experience angioedema without an identifiable etiology with\n nl-C1INH function and no family history of angioedema. Idiopathic angioedema is further characterized into histaminergic or nonhistaminergic angioedema, depending on the response to high-dose antihistamines. Given the considerable impact of angioedema, physicians and patients must collaborate\n to craft personalized management strategies. For those with HAE, short- and long-term prophylaxis and on-demand therapy must be considered.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250013","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:32:27Z","timestamp":1747441947000},"page":"185-191","source":"Crossref","is-referenced-by-count":9,"title":["Angioedema without urticaria: Diagnosis and management"],"prefix":"10.2500","volume":"46","author":[{"given":"Marielle C.","family":"Young","sequence":"first","affiliation":[{"name":"From the Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[{"name":"From the Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.anai.2022.08.003","article-title":"Isolated angioedema: a review of classification and update on management","volume":"129","author":"Kesh","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1684\/ejd.2014.2276","article-title":"Recurrent angioedema: diagnosis strategy and biological aspects","volume":"24","author":"Bouillet","year":"2014","journal-title":"Eur J Dermatol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/ACI.0000000000000633","article-title":"Angioedema without urticaria: novel findings which must be measured in clinical setting","volume":"20","author":"Veronez","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2500\/aap.2013.34.3640","article-title":"National estimates of emergency department visits for angioedema and allergic reactions in the United States","volume":"34","author":"Kelly","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"B5","first-page":"455","article-title":"Drug-induced angioedema: experience of Italian emergency departments","volume":"9","author":"Bertazzoni","year":"2014","journal-title":"Intern Emerg Med"},{"key":"B6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2500\/aap.2014.35.3787","article-title":"Prognostic factors in outcome of angioedema in the emergency department","volume":"35","author":"Felder","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"B7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(11)60935-5","article-title":"Hereditary angio-oedema","volume":"379","author":"Longhurst","year":"2012","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"Banerji","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/JAA.S245161","article-title":"Clinical features and disease course of primary angioedema patients in a tertiary care hospital","volume":"13","author":"Pall","year":"2020","journal-title":"J Asthma Allergy"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1503\/cmaj.060535","article-title":"Angioedema without urticaria: a large clinical survey","volume":"175","author":"Zingale","year":"2006","journal-title":"CMAJ"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jaci.2013.03.034","article-title":"A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema","volume":"131","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.iac.2017.04.001","article-title":"Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade","volume":"37","author":"Kaplan","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"B13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2500\/aap.2019.40.4267","article-title":"Hereditary and acquired angioedema","volume":"40","author":"Patel","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/humu.23917","article-title":"SERPING1 mutation update: mutation spectrum and C1 inhibitor phenotypes","volume":"41","author":"Ponard","year":"2020","journal-title":"Hum Mutat"},{"key":"B15","doi-asserted-by":"crossref","first-page":"S03","DOI":"10.2500\/aap.2020.41.200040","article-title":"Definition and classification of hereditary angioedema","volume":"41","author":"Proper","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2500\/aap.2024.45.240010","article-title":"Hereditary angioedema with normal C1 esterase inhibitor: current paradigms and clinical dilemmas","volume":"45","author":"Radojicic","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(00)02483-1","article-title":"Hereditary angioedema with normal C1-inhibitor activity in women","volume":"356","author":"Bork","year":"2000","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jaci.2021.01.011","article-title":"Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation","volume":"148","author":"Bork","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2500\/aap.2011.32.3411","article-title":"Hereditary angioedema: historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis","volume":"32","author":"Khan","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"B20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2500\/aap.2009.30.3279","article-title":"Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks","volume":"30","author":"Prematta","year":"2009","journal-title":"Allergy Asthma Proc"},{"key":"B21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF03042666","article-title":"Hypovolemic shock caused by ascites in hereditary angioedema","volume":"93","author":"Bork","year":"1998","journal-title":"Med Klin (Munich)"},{"key":"B23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaip.2016.12.032","article-title":"Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency","volume":"5","author":"Zanichelli","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaip.2017.03.003","article-title":"Randomized trial of icatibant for angiotensin-converting enzyme inhibitor-induced upper airway angioedema","volume":"5","author":"Sinert","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B27","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J Hypertens"},{"key":"B28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/JAA.S205709","article-title":"Idiopathic angioedema: current challenges","volume":"13","author":"Belb\u00e9zier","year":"2020","journal-title":"J Asthma Allergy"},{"key":"B29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/joim.12304","article-title":"Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients","volume":"277","author":"Mansi","year":"2015","journal-title":"J Intern Med"},{"key":"B30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.iac.2017.03.001","article-title":"Histaminergic angioedema","volume":"37","author":"Busse","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"B31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaip.2014.12.007","article-title":"Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria","volume":"3","author":"Amin","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/14656566.2017.1282461","article-title":"Current and future therapies for the treatment of histamine-induced angioedema","volume":"18","author":"James","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"B33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2340\/00015555-2496","article-title":"A review of international recommendations for the diagnosis and management of chronic urticaria","volume":"97","author":"Beck","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13601-017-0164-9","article-title":"Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials","volume":"7","author":"Bucher","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"B35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","article-title":"US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency","volume":"1","author":"Zuraw","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2009.12.004","article-title":"Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?","volume":"104","author":"Lunn","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2500\/aap.2015.36.3820","article-title":"Facilitating home-based treatment of hereditary angioedema","volume":"36","author":"Bernstein","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B38","doi-asserted-by":"crossref","first-page":"100627","DOI":"10.1016\/j.waojou.2022.100627","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update","volume":"15","author":"Maurer","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2500\/aap.2022.43.210086","article-title":"Guidelines for management of hereditary angioedema: What is new? What is missing?","volume":"43","author":"Radojicic","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B40","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1537-2995.2005.00602.x","article-title":"Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema","volume":"45","author":"Bork","year":"2005","journal-title":"Transfusion"},{"key":"B41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000381341","article-title":"Home therapy with plasma-derived C1 inhibitor: a strategy to improve clinical outcomes and costs in hereditary angioedema","volume":"166","author":"Petraroli","year":"2015","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000003\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:32:56Z","timestamp":1761021176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,1]]}},"alternative-id":["1088-5412(20250501)46:3L.185;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250013","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}